Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
St Phi Therapeutics Co. Ltd. is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is confined to 1 distinct examiner and 1 distinct art unit, reflecting a focused prosecution strategy. In the pharmaceutical industry, such concentration often indicates a single key patent application undergoing review.
CLAIRE M KAUFMAN is the busiest examiner for the company, with 1 pending office action currently assigned. This 1 busiest examiner pending action represents the total pending workload for the company. Because the portfolio involves only 1 distinct examiner, the immediate success of the company's patenting efforts depends on the specific requirements of this individual. The presence of 1 distinct art unit suggests that the company is not currently navigating the complexities of multiple different examination groups within the USPTO's biotechnology divisions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KAUFMAN, CLAIRE M | 1 | 63.3% | +51.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18731402 | Chimeric Natural Killer Cell Receptors and Method of Using Thereof | KAUFMAN, CLAIRE M | 37d overdue |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18731402 | Chimeric Natural Killer Cell Receptors and Method of Using Thereof | KAUFMAN, CLAIRE M | 1674 | §103 | Final Rejection | 37d overdue | Pending | Jun 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSt Phi Therapeutics Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Claire M Kaufman has the most, with 1 of St Phi Therapeutics Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
